These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19893593)

  • 1. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
    Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
    Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.
    Higuchi H; Bronk SF; Bateman A; Harrington K; Vile RG; Gores GJ
    Cancer Res; 2000 Nov; 60(22):6396-402. PubMed ID: 11103804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
    Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
    J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
    Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
    Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NF-kappaB in fusogenic membrane glycoprotein causing HL-60 cell death: implications for acute myeloid leukemia.
    Tan L; Jia H; Liu R; Wu J; Han H; Zuo Y; Yang S; Huang W
    Cancer Lett; 2009 Jan; 273(1):114-21. PubMed ID: 18783878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
    Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
    Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
    Katiyar SK; Meeran SM; Katiyar N; Akhtar S
    Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
    Zhang J; Frolov I; Russell SJ
    J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
    Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
    Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
    Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.
    Bateman AR; Harrington KJ; Kottke T; Ahmed A; Melcher AA; Gough MJ; Linardakis E; Riddle D; Dietz A; Lohse CM; Strome S; Peterson T; Simari R; Vile RG
    Cancer Res; 2002 Nov; 62(22):6566-78. PubMed ID: 12438252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.
    Bateman A; Bullough F; Murphy S; Emiliusen L; Lavillette D; Cosset FL; Cattaneo R; Russell SJ; Vile RG
    Cancer Res; 2000 Mar; 60(6):1492-7. PubMed ID: 10749110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
    Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
    Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.
    Guedan S; Grases D; Rojas JJ; Gros A; Vilardell F; Vile R; Mercade E; Cascallo M; Alemany R
    Gene Ther; 2012 Nov; 19(11):1048-57. PubMed ID: 22113313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy.
    Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG
    Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
    Hoffmann D; Bangen JM; Bayer W; Wildner O
    Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
    Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.
    Guedan S; Gros A; Cascallo M; Vile R; Mercade E; Alemany R
    Gene Ther; 2008 Sep; 15(17):1240-5. PubMed ID: 18509378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.